Key clinical point: Entrectinib demonstrated antitumor activity in children and adolescents with recurrent or refractory solid tumors.
Major finding: Twelve patients responded to entrectinib, and all responders had fusions or mutations in target genes – NTRK1/2/3 (TRKA/B/C), ROS1, or ALK.
Study details: Ongoing phase 1/1b trial of 29 patients.
Disclosures: The trial is sponsored by Hoffman-La Roche Ltd and supported by Alex’s Lemonade Stand Center of Excellence. The presenter has relationships with Lilly, Genentech/Roche, and Novartis.
Robinson GW et al. ASCO 2019. Abstract 10009.